CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China
SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (&ldq … Read More
